Europe Antiviral Drugs Market Size & Outlook, 2022-2030
Europe antiviral drugs market, 2018-2030 (US$M)
Related Markets
Europe antiviral drugs market highlights
- The Europe antiviral drugs market generated a revenue of USD 25,954.8 million in 2022.
- The market is expected to grow at a CAGR of -1.9% from 2023 to 2030.
- In terms of segment, hiv was the largest revenue generating application in 2022.
- Herpes is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2023 to 2030.
Europe data book summary
| Market revenue in 2022 | USD 25,954.8 million |
| Market revenue in 2030 | USD 22,308.0 million |
| Growth rate | -1.9% (CAGR from 2022 to 2030) |
| Largest segment | Hiv |
| Fastest growing segment | Herpes |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | HIV, Hepatitis, Herpes, Influenza |
| Key market players worldwide | Roche Holding AG, GSK PLC ADR, AbbVie Inc, Merck & Co Inc, Johnson & Johnson, Bristol-Myers Squibb Co, Dr Reddy's Laboratories Ltd ADR, Aurobindo Pharma |
Other key industry trends
- In terms of revenue, Europe region accounted for 35.6% of the global antiviral drugs market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 8,502.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antiviral Drugs Market Scope
Antiviral Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe antiviral drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antiviral drugs market will help companies and investors design strategic landscapes.
Hiv was the largest segment with a revenue share of 34.38% in 2022. Horizon Databook has segmented the Europe antiviral drugs market based on hiv, hepatitis, herpes, influenza covering the revenue growth of each sub-segment from 2018 to 2030.
Europe held the second-largest share in the market in 2022, following North America. However, the market is expected to be propelled by an increase in research funding and the presence of local key market players in this region. The number of biopharmaceutical companies is growing in Europe owing to increasing investments.
For instance, in December 2021, the European Commission announced the expansion of Remdesivir for treating adults with a high risk of COVID-19 progression. Moreover, the population in Europe is rapidly aging. According to the UN, people over 65 constitute 19% of the population, accounting for about 183 million.
This population is at a relatively high risk of developing viral infectious diseases, including influenza, as the risk of developing flu and hospitalization rates are relatively higher in elder patients. Thus, owing to these factors, the region is expected to witness exponential growth opportunities during the forecast period.
Reasons to subscribe to Europe antiviral drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe antiviral drugs market databook
-
Our clientele includes a mix of antiviral drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe antiviral drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Europe antiviral drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe antiviral drugs market size, by country, 2018-2030 (US$M)
Europe Antiviral Drugs Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
